PROGRAM - Monday, May 17, 2010

PROGRAM - MONDAY, MAY 17, 2010
 
7:00AM - 8:00AM
EDUCATIONAL SYMPOSIUM (Sponsored by Medaxial)
THE 7 ESSENTIALS OF SUCCESSFUL HEALTH ECONOMIC COMMUNICATION Symposium Description »
8:00AM - 8:30AM
EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I
8:30AM - 10:30AM
WELCOME & FIRST PLENARY SESSION

MEETING PROGRAM OVERVIEW
Daniel C. Malone RPh, PhDDaniel C. Malone RPh, PhD
Professor, College of Pharmacy, University of Arizona, Tucson, AZ, USA

 

PRESIDENTIAL ADDRESS
Michael Barry PhD Michael Barry PhD
2009-2010 ISPOR President & Clinical Director, National Centre for Pharmacoeconomics, St. James’s Hospital and Senior Lecturer in Clinical Pharmacology, Trinity College Dublin, Dublin, Ireland

  Personalized Medicine: The Value of Targeted Therapy
The mapping of the human genome has opened the gate for developing therapies that benefit select subsets of the population. This plenary session will provide an introduction to pharmacogenomics and pharmacogenetics, debate the role of genotyping, present case studies where therapies are being tailored to specific genetic disposition, and discuss the role of pharmacoeconomics and outcomes research in defining the value of personalized medicine.

9:00 – 9:20 AM Scott D. Ramsey MD, PhD Moderator/Speaker: Scott D. Ramsey MD, PhD, Full Member and Professor, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
     
9:20 – 9:40 AM Lawrence J. Lesko PhD, FCP Speaker: Lawrence J. Lesko PhD, FCP, Director, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
     
9:40 – 10:00 AM Ralph J. Coates PhD Speaker: Ralph J. Coates PhD, Associate Director for Science, Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, GA, USA
     
10:00 – 10:20 AM Robert S. Epstein MD, MS Speaker: Robert S. Epstein MD, MS, Chief Medical Officer and President, Medco Research Institute, Medco Health Solutions Inc., Franklin Lakes, NJ, USA
10:20 – 10:30 AM   DISCUSSION
10:30AM-11:00AM
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I
11:00AM-12:00PM
ISSUE PANELS – SESSION I
 

Clinical Outcomes Research Issues

11:00AM-12:00PM
IP1: HETEROGENEITY OF TREATMENT EFFECTS: A REASSESSMENT IN THE ERA OF COMPARATIVE EFFECTIVENESS RESEARCH
Moderator: David Thompson PhD, Senior Vice President, Health Economics & Strategic Consulting, i3 Innovus, Medford, MA, USA
Panelists: John Cook PhD, Senior Director, Scientific Staff, Health Economics Statistics, Merck & Co., Inc., North Wales, PA, USA; Sheldon Greenfield MD, Professor of Medicine and Executive Director, Center for Health Policy Research, School of Medicine, University of California, Irvine, Irvine, CA, USA
  Health Policy Development Using Outcomes Research Issues
11:00AM-12:00PM
IP2: MEDICARE, HEALTH REFORM AND THE FUTURE OF EVIDENCE REQUIREMENTS
Moderator: Peter J. Neumann ScD, Professor, Tufts University School of Medicine and Director, The Center for the Evaluation of Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
Panelists: Steve E. Phurrough MD, MPA, (Formerly at CMS), Chief Operating Officer and Senior Clinical Director, Center for Medical Technology Policy, Baltimore, MD, USA; Penny Mohr MA, (Formerly at CMS), Vice President, Programs, Center for Medical Technology Policy, Baltimore, MD, USA; James Chambers MPharm, MSc, Project Director, The Center for the Evaluation of Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
11:00AM-12:00PM
IP3: PERSPECTIVES ON COMPARATIVE EFFECTIVENESS RESEARCH (CER): VIEWS FROM DIVERSE CONSTITUENCIES
Moderator: Howard Birnbaum PhD, Principal, Analysis Group, Inc., Boston, MA, USA
Panelists: Marc L. Berger MD, Vice President, Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA; Jean Slutsky PA, MSPH, Director, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, Rockville, MD, USA; Robert S. Epstein MD, MS, Chief Medical Officer and President, Medco Research Institute, Medco Health Solutions Inc., Franklin Lakes, NJ, USA
  Patient-Reported Outcomes Research Issues
11:00AM-12:00PM
IP4: PATIENT-REPORTED OUTCOMES FOR ADVERSE EVENT MONITORING
Moderator: Ethan Basch MD, MSc, Principal Investigator, Health Outcomes Group, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Panelists: Laurie B. Burke RPh, MPH, Director, Study Endpoint and Label Development, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA; Bryce Reeve PhD, Program Director, National Cancer Institute, Bethesda, MD, USA; Stephen Joel Coons PhD, Director, Patient-Reported Outcomes (PRO) Consortium, Critical Path Institute, Tucson, AZ, USA
12:00PM-1:45PM
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I
12:30PM-1:30PM
EDUCATIONAL SYMPOSIUM (Sponsored by IMS)
WILL COMPARATIVE EFFECTIVENESS RESEARCH SURVIVE HEALTH REFORM? Symposium Description »
1:45PM-2:45PM
RESEARCH PODIUM PRESENTATIONS – SESSION I
1:45PM-2:45PM

RESEARCH ON DATABASE METHODS

DB1: DEVELOPMENT AND VALIDATION OF A MODEL TO PREDICT VIROLOGIC FAILURE USING ADMINISTRATIVE CLAIMS

Juday T1, Jing Y1, Chang E2, Broder M2
1Bristol-Myers Squibb, Plainsboro, NJ, USA, 2Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA

DB2: EVALUATION OF AGREEMENT BETWEEN INTERNET-BASED SELF- AND PROXY-REPORTED HEALTH CARE UTILIZATION AND ADMINISTRATIVE HEALTH CARE CLAIMS

Palmer L1, Johnston SS1, Rousculp M2, Nichol KL3, Mahadevia PJ2
1Thomson Reuters, Washington, DC, USA, 2MedImmune, Gaithersburg, MD, USA, 3University of Minnesota, Minneapolis, MN, USA

DB3: MUCH ADO ABOUT THE LACK OF SOCIO-ECONOMIC COVARIATES IN ADMINISTRATIVE CLAIMS DATA

Borah B
i3 Innovus, Eden Prairie, MN, USA

DB4: ACCOUNTING FOR THE RELATIONSHIP BETWEEN PER DIEM COST AND LOS WHEN ESTIMATING HOSPITALIZATION COSTS

Stolar M1, Hu MY2, Ishak K3, Wang Y2, Williams GC2, Ferguson J2, Getsios D4, Alvarez P1
1United BioSource Corporation, Lexington, MA, USA, 2The Medicines Company, Parsippany, NJ, USA, 3United BioSource Corporation, Dorval, QC, Canada, 4United BioSource Corporation, Halifax, NS, Canada

1:45PM-2:45PM

HEALTH CARE EXPENDITURES STUDIES

HE1: COST-EFFECTIVENESS OF 1ST LINE CHEMOTHERAPY REGIMENS IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER AMONG PATIENTS RECEIVING CARE IN THE OUTPATIENT COMMUNITY SETTING

Hoverman JR1, Pohl G2, Gruschkus SK3, Marciniak M2, Forsyth M3, Peltz G2
1Texas Oncology, Dallas, TX, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Healthcare Informatics, The Woodlands, TX, USA

HE2: HEALTH CARE COSTS OF METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK - FINDINGS FROM LINKED SEER-MEDICARE DATA

Parthan A1, Kulakodlu M2, Deflin M1, Taylor D3, Barber B4, Zhao Z4
1i3 Innovus, San Francisco, CA, USA, 2i3 Innovus, Eden Prairie, MN, USA, 3i3 Innovus, Medford, MA, USA, 4Amgen Inc., Thousand Oaks, CA, USA

HE4: CHARACTERIZATION OF FREQUENT HOSPITAL EMERGENCY DEPARTMENT (ED) USE BY UN- OR UNDERINSURED PERSONS

Khurshid A1, Strassels S2
1Integrated Care Collaboration, Austin, TX, USA, 2University of Texas at Austin, Austin, TX, USA

1:45PM-2:45PM

HEALTH TECHNOLOGY ASSESSMENT STUDIES

HT1: COMPARATIVE-EFFECTIVENESS VERSUS COST-EFFECTIVENESS: A COMPARISON OF THE FRENCH AND SCOTTISH APPROACHES TO SINGLE TECHNOLOGY ASSESSMENT (STA)

Bending MW1, Hutton J1, McGrath C2
1University of York, York, UK, 2Pfizer, Walton on the Hill, Surrey, UK

HT2: VARIABILITY IN UTILIZATION OF INNOVATIVE DRUGS IN EUROPE AS A RESULT OF HEALTH TECHNOLOGY ASSESSMENT AND FUNDING PROCEDURES: EXAMPLES OF TRASTUZUMAB AND CETUXIMAB

Toumi M1, Misset JL2, Cristeau O1, Krukowski L3, Aballea S4, Lamure M5
1University Claude Bernard Lyon 1, Lyon, France, 2Hopital Saint Louis, Paris, France, 3Synovate, London, UK, 4CREATIV-CEUTICAL, Paris, France, 5University Claude Bernard Lyon 1, Paris, France

HT3: MULTICRITERIA DECISION ANALYSIS (MCDA) FOR DRUG COVERAGE DECISION BY A PUBLIC HEALTH PLAN: CASE STUDY OF TRAMADOL FOR CHRONIC NON-CANCER PAIN (CNCP) IN CANADA

Tony M1, Goetghebeur M1, Wagner M1, Khoury H1, Rindress D1, Oh P2
1BioMedCom Consultants Inc., Dorval, QC, Canada, 2University of Toronto, Toronto, ON, Canada

HT4: PRAGMATIC CLINICAL TRIALS FOR DRUG APPROVAL: IS IT REALISTIC?

Mohr P1, Sonnad S2, Mullins CD3, Whicher D1, Goldsack J2, Tunis SR1
1Center for Medical Technology Policy, Baltimore, MD, USA, 2University of Pennsylvania, Philadelphia, PA, USA, 3University of Maryland School of Pharmacy, Baltimore, MD, USA

1:45PM-2:45PM

RESEARCH ON PRO METHODS (INCLUDING UTILITIES)

PR1: INCORPORATING TARIFF-LEVEL UNCERTAINTY AROUND ESTIMATES FROM THE CATALOGUE OF EQ-5D SCORES

Sullivan P1, Ghushchyan VH2, Slejko JF2
1Regis University School of Pharmacy, Denver, CO, USA, 2University of Colorado Denver, Aurora, CO, USA

PR2: EVALUATING THE MEASUREMENT PROPERTIES OF AN AUGMENTED EQ-5D WITH THE INCLUSION OF TWO SINGLE QUALITY-OF-LIFE (QOL) INDICATORS USING THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)

Gu NY1, Bond TG2, Craig BM3
1Pharmerit North America, LLC, Bethesda, MD, USA, 2James Cook University, Townsville, QLD, Australia, 3Moffitt Cancer Center, Tampa, FL, USA

PR3: NATIONAL CULTURE AND EQ-5D VALUE SETS

Bailey H1, Kind P2
1The University of the West Indies, Maracas Valley, Trinidad and Tobago, 2University of York, York, UK

PR4: ARE HEALTH STATES "TIMELESS"? A TEST OF THE UTILITY INDEPENDENCE ASSUMPTION: COMPARING A REPEATED MEASURES DESIGN AND LATENT GROWTH MODELING

Franic D1, Gafni A2, Vandenberg R1
1University of Georgia, Athens, GA, USA, 2McMaster University, Hamilton, ON, Canada

1:45PM-2:45PM

RISK MANAGEMENT STUDIES

RM1: COMPARATIVE PERFORMANCE OF RISK ADJUSTMENT MEASURES IN A SAMPLE OF COMMERCIALLY-INSURED PATIENTS UNDER AGE 65 - TWO SIMPLE MEASURES OUTPERFORM CURRENT STANDARDS

 Fowler R, Johnston SS
Thomson Reuters, Washington, DC, USA

RM2: IMPACT OF ADHERENCE WITH STATIN THERAPY ON HOSPITALIZATION RISK AND MORTALITY AMONG PATIENTS WITH DIABETES

 Yang Y, Banahan BF, P
ace PF University of Mississippi, University, MS, USA

RM3: RISK OF FALLS AND FRACTURES IN OLDER ADULTS USING ATIPSYCHOTIC AGENTS- A PROPENSITY-MATCHED RETROSPECTIVE COHORT STUDY

 Mehta S, Aparasu RR, Chen H, Johnson M
University of Houston, Houston, TX, USA

RM4: CONFOUNDING EFFECT OF AGE IN THE ASSOCIATION OF CARDIOVASCULAR RISK AND DIETARY SUPPLEMENT USE AMONG US ADULTS

 Yu S1, Shaw JW1, Crawford SY1, Groo V2
1University of Illinois at Chicago, Chicago, IL, USA, 2University of Illinois at Chicago, Chicago , IL, USA

3:00PM-4:00PM
WORKSHOPS – SESSION I
 

Clinical Outcomes Research Issues

3:00PM-4:00PM
W1: COMPARATIVE EFFECTIVENESS RESEARCH FOR PERSONALIZED MEDICINE
Discussion Leaders: James Signorovitch PhD, Manager, Analysis Group, Inc., Boston, MA, USA; Eric Q. Wu PhD, Vice President, Analysis Group, Inc., Boston, MA, USA; Lee-Jen Wei PhD, Professor, Biostatistics, Harvard University, Boston, MA, USA
  Economic Outcomes Research
3:00PM-4:00PM
W2: CHALLENGES IN DESIGNING, CONDUCTING AND ANALYSING MULTINATIONAL ECONOMIC CLINICAL TRIALS
Discussion Leaders: Michael Drummond PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK; Andrea Manca PhD, MSc, Senior Research Fellow, Centre for Health Economics, University of York, York, UK; Arie Barlev PhD, Senior Manager, Global Health Economics, Amgen, Thousand Oaks, CA, USA
3:00PM-4:00PM
W3: COST OF ILLNESS STUDIES: A FRESH LOOK AT ONE OF THE FOUNDATIONS OF HEALTH POLICY AND OUTCOMES RESEARCH
Discussion Leaders: Tami Mark PhD, MBA, Director, Thomson Reuters, Washington, DC, USA; Dan Huse MA, VP, Outcomes Research, Thomson Reuters, Cambridge, MA, USA; Joel W. Hay PhD, Associate Professor, Pharmaceutical Economics & Policy, University of Southern California, Los Angeles, CA, USA
  Health Care Policy Development Using Outcomes Research
3:00PM-4:00PM
W4: THE 2009 UPDATE OF THE AMCP FORMAT FOR FORMULARY COVERAGE AND REIMBURSEMENT DECISIONS IN THE US
Discussion Leaders: Richard Fry RPh, Director of Programs, Foundation for Managed Care Pharmacy, Alexandria, VA, USA; Sean Sullivan PhD, RPh, MS, Professor and Director, Pharmaceutical Outcomes Research & Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA; Pete Penna PharmD, President, Formulary Resources, LLC, Mercer Island, WA, USA; Iris Tam PharmD, Director, Institutional Medical Communications, Genentech, South San Francisco, CA, USA
  Patient-Reported Outcomes/PREFERENCE-BASED Research
3:00PM-4:00PM
W5: REGULATORY EVALUATION OF PATIENT-REPORTED OUTCOME MEASURES (PROS) USED IN CLINICAL TRIALS
Discussion Leaders: Laurie B. Burke RPh, MPH, Director, Study Endpoints and Label Development, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA; June Cai MD, Endpoints Reviewer, Study Endpoints and Label Development, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA; Ann Marie Trentacosti MD, Endpoints Reviewer, Study Endpoints and Label Development, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
  USE OF REAL WORLD DATA
3:00PM-4:00PM
W7: HOW TO USE ADMINISTRATIVE CLAIMS DATABASES TO ASSESS LONG TERM CLINICAL BENEFIT OF MEDICATION INITIATION FROM AN EVOLUTIONARY PERSPECTIVE: TRADITIONAL ANALYTICAL APPROACHES VS. NOVEL USE OF TIME SERIES ANALYSIS
Discussion Leaders: Peter Sun MD, PhD, Vice President, Kailo Research Group, Indianapolis, IN, USA; Joanne R. Chang PhD, MD, Vice President, Evidence Based Medicine, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Jie Zhang PhD, Director, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
4:00PM-4:15PM
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I
4:15PM-5:15PM
WORKSHOPS – SESSION II
 

Clinical Outcomes Research Issues

4:15PM-5:15PM
W8: MODEL ASSUMPTIONS IN MIXED TREATMENT COMPARISONS (MTCS): WHY THEY MATTER AND WHY YOU SHOULD CARE
Discussion Leaders: Rachael Fleurence PhD, Senior Research Scientist, Center for Health Economics and Science Policy, United BioSource Corporation, Bethesda, MD, USA; Kyle Fahrbach PhD, Senior Biostatistician, United BioSource Corporation, Lexington, MA, USA; David Vanness PhD, Assistant Professor, Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
  Economic Outcomes Research
4:15PM-5:15PM
W9: THRESHOLD ANALYSIS TO CHARACTERIZE PARAMETER UNCERTAINTY IN COST-EFFECTIVENESS ANALYSES WITH AMBIGUOUS RESULTS
Discussion Leaders: Amy O'Sullivan PhD, Director, Health Economics & Outcomes Research, i3 Innovus, Medford, MA, USA; Milton C. Weinstein PhD, Henry J Kaiser Professor of Health Policy & Management, Harvard School of Public Health, Boston, MA, USA
4:15PM-5:15PM
W10: WHAT CAN RESOURCE ALLOCATION IN SITUATIONS OF EXTREME SCARCITY TELL US ABOUT THE ROLE OF THE QALY IN PRIORITY SETTING?
Discussion Leaders: Peter Kolominsky-Rabas PhD, MBA, Scientific Director, Interdisziplinäres Zentrum für Public Health (IZPH) der Universität Erlangen-Nürnberg, Erlangen, Germany; Georgia Mitsi PhD, MBA, MSc, Manager, United BioSource Corporation, Lexington, MA, USA; J. Jaime Caro MD, Senior Vice President of Health Economics, United BioSource Corporation, Lexington, MA, USA
  Health Care Policy Development Using Outcomes Research
4:15PM-5:15PM
W11: YOUR ROLE IN INTERPRETING AND APPROPRIATELY COMMUNICATING CER RESULTS IN A HIGHLY CHARGED ENVIRONMENT
Discussion Leaders: Robert Dubois PhD, MD, Chief Medical Officer, Cerner LifeSciences, Beverly Hills, CA, USA; Jean Slutsky PA, MSPH, Director, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, Rockville, MD, USA; Lester Paul MD, MS, Vice President, Clinical & Scientific Affairs, National Pharmaceutical Council, Reston, VA, USA; Brian Sweet RPh, MBA, Chief Pharmacy Officer, WellPoint, Grand Island, NY, USA
  Patient-Reported Outcomes/PREFERENCE-BASED Research
4:15PM-5:15PM
W12: INTERPRETATION OF PRO TRIAL RESULTS TO SUPPORT FDA LABELING CLAIMS
Discussion Leaders: Kathleen W. Wyrwich PhD, Senior Research Leader, Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD, USA; Laurie B. Burke RPh, MPH, Director, Study Endpoints and Label Development, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA; Ann Marie Trentacosti MD, Endpoints Reviewer, Study Endpoints and Label Development, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
  USE OF REAL WORLD DATA
4:15PM-5:15PM
W13: PROJECTING DISEASE PREVALENCE: THE IMPACT OF METHODOLOGY– EXAMPLES IN ATRIAL FIBRILLATION
Discussion Leaders: Kathy L. Schulman MA, Principal, Outcomes Research Solutions, Inc., Bolton, MA, USA; Stephen S. Johnston MA, Research Leader, Outcomes Research, Thomson Reuters, Washington, DC, USA; Jay Lin PhD, MBA, Director, Evidence Based Medicine, sanofi-aventis U.S., Bridgewater, NJ, USA; Dan Huse MA, Vice President, Outcomes Research, Thomson Reuters, Cambridge, MA, USA
4:15PM-5:15PM
W14: POST-APPROVAL RESEARCH: ALTERNATIVE STUDY DESIGNS AND OPERATIONAL CONSIDERATIONS
Discussion Leaders: Cynthia Verst PharmD, MS, Senior Vice President, Late Phase Research, i3 Innovus, Cold Spring, KY, USA; Michael Drummond PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK; Myoung Kim PhD, MA, MBA, Director, Health Economics & Outcomes Research, Ortho-McNeil Janssen Scientific Affairs, Raritan, NJ, USA; Frank Lobeck PharmD, Vice President, Americas, Late Phase Research, i3 Innovus, Dexter, MI, USA
5:30PM-6:30PM
ISPOR FORUMS
5:30PM-6:30PM ISPOR GOOD RESEARCH PRACTICES RECOMMENDATIONS ON THE FDA’S GUIDANCE FOR INDUSTRY PATIENT REPORTED OUTCOME MEASURES: USE IN MEDICAL PRODUCT DEVELOPMENT TO SUPPORT LABELING CLAIMS
The FDA guidance on the use of patient reported outcomes (PRO) measures has shaped much of the industry-funded PRO research during the past three years.  ISPOR have developed several good research practices for implementing this FDA guidance. During this Forum, the development of the content for a new PRO instrument to assure that the instrument is relevant and important to the patient’s condition and its treatment as well as the development and validation of PROs for use in children and adolescents will be discussed. Presented by the ISPOR Patient Reported Outcomes Good Research Practices Task Force

ISPOR Good Research Practices for Establishing and Reporting Evidence of the Content Validity of New PRO Instruments
Speakers: Laurie B. Burke RPh, MPH, Director, Study Endpoints and Label Developments, Office of New Drugs, CDER, FDA, Silver Spring, MD, USA; Mona L. Martin RN, MPA, Executive Director, Health Research Associates, Inc, Seattle, WA, USA; Chad Gwaltney PhD, Assistant Professor (Research), Department of Community Health, Brown University, Providence, RI, USA and Scientific Consultant, PRO Consulting, Pittsburgh, PA, USA

ISPOR Good Research Practices for the Assessment of Patient Reported Outcomes in Children and Adolescents
Speaker: Louis Matza PhD, Chair, ISPOR PRO Assessment of Children & Adolescents Task Force and Research Scientist, Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD, USA
5:30PM-6:30PM ISSUES AND CHALLENGES IN THE DEVELOPMENT AND REIMBURSEMENT OF PERSONALIZED MEDICINE: HOW CAN HEALTH ECONOMICS AND OUTCOMES RESEARCH HELP?
As global health decision makers struggle to balance quality and cost of care, personalized medicine is beginning to emerge as one mechanism for potentially addressing both goals in early initial applications. The ISPOR Personalized Medicine Special Interest Group (PM SIG) will present an overview of ongoing work on key gaps, challenges, and opportunities associated with the use of personalized medicine approaches, and specifically pharmacogenomics, to improve the safety, effectiveness and cost of care. Perspectives of the researcher, diagnostic and drug manufacturer, health technology assessor, and payer will be presented, along with an initial overview of opportunities to better leverage health economics and outcomes research to improve decision making from bench to bedside and address key decision maker questions across the health continuum.  Presented by the ISPOR Personalized Medicine Special Interest Group

Moderator & Speaker: Eric Faulkner MPH, Chair, ISPOR Personalized Medicine Development and Reimbursement Working Group, Senior Director, RTI Health Solutions, Executive Director, Genomics Biotech Institute, National Association of Managed Care Physicians, RTP, NC, USA
Speakers: Daniel C. Malone PhD, RPh, Professor, College of Pharmacy, University of Arizona, Tucson, AZ, USA;  Finley Austin PhD, US Head External Innovation Environment, Roche, Nutley, NJ, USA; John Watkins RPh, MPH, BCPS, Pharmacy Manager, Formulary Development, Premera Blue Cross and Clinical Associate Professor of Pharmacy, University of Washington, Seattle, WA, USA; Dave Veenstra, PhD, PharmD, Associate Professor, University of Washington, Seattle, WA, USA

5:30PM-6:30PM MOVING FORWARD WITH HTA FOR MEDICAL DEVICES & DIAGNOSTIC PRODUCTS! THE ISPOR GLOBAL HEALTH CARE SYSTEMS ROAD MAP
ISPOR Global Health Care Systems Road Map will be used as a tool to discuss and compare the similarities and differences between the decision- making bodies, reimbursement and pricing approval process for products being assessed – pharmaceuticals, medical devices or diagnostics. Road maps for medical devices & diagnostics will be discussed together with some pragmatic solutions to the current issues associated with assessing their value. Presented by the ISPOR HTA Special Interest Group

Moderator & Speaker: Stefan Holmstrom MSc, Co-chair, ISPOR Global Health Care Reimbursement Systems and Decision Processes Working Group, Director HEOR, Astellas Pharma Europe, Leiderdorp, The Netherlands
Speakers: Annie Chicoye PhD, Co-chair, ISPOR Health Technology Assessment of Medical Devices & Diagnostics Working Group, Senior Principal Director Pricing & Market Access, IMS HEALTH, Puteaux-Cedex, France; Feng Xie PhD, MSc, Leadership member, ISPOR Health Technology Assessment of Medical Devices & Diagnostics Working Group, Assistant Professor, PATH Research Institute, McMaster University, Hamilton, ON, Canada; Susan Garfield MSc, Leadership member, ISPOR Health Technology Assessment of Medical Devices & Diagnostics Working Group, Vice President, Bridgehead International, Wayland, MA, USA

5:30PM-6:30PM GOOD RESEARCH PRACTICES FOR COMPARATIVE EFFECTIVENESS RESEARCH AND USE OF INDIRECT TREATMENT COMPARISONS IN HEALTH CARE DECISIONS
The goal of the ISPOR Indirect Treatment Comparisons Task Force is to develop good research practices on indirect treatment comparisons that addresses key issues from the outcomes researcher’s perspective as well as key issues from the health care decision-maker’s perspective.  The content of the Task Force draft reports will be discussed. Presented by the ISPOR Indirect Treatment Comparison Task Force

Moderator: David Thompson PhD, Senior Vice President, Health Economics & Strategic Consulting, i3 Innovus, Medford, MA, USA
Speakers: David C. Hoaglin PhD, Principal Statistician, Abt Bio-Pharma Solutions, Inc, Lexington, MA, USA; Jeroen Jansen PhD, MSc, Research Director - Market Access, Mapi Values, Boston, MA, USA; Rachael Fleurence PhD, MBA, MSc, Research Scientist and Director of Health Economics, United BioSource Corporation, Bethesda MD, USA; Cornelis Boersma PhD, MSc, Post-doc/Consultant-Director, University of Groningen / HECTA, Groningen, The Netherlands; Beth Devine PharmD, MBA, PhD, Research Associate Professor, Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy, Adjunct Research Associate Professor, Biomedical & Health Informatics, School of Medicine, University of Washington, Seattle, WA, USA; Neil Hawkins PhD, Director, Oxford Outcomes Ltd, Oxford, UK; Robbin Itzler PhD, Associate Director, Merck Research Laboratories, North Wales, PA, USA

5:30PM-6:30PM COMPLIANCE ISSUES AND WHY MEASUREMENT AND ANALYSIS ARE IMPORTANT
Compliance research requires an understanding about the best methodology to conduct studies including: randomized controlled clinical trials, observational, and quasi- experimental studies. Key considerations for researchers regarding the design, analysis and reporting of results of such studies will be reviewed. Presented by the ISPOR Medication Compliance & Persistence Special Interest Group

Moderator and Speaker: Femida Gwadry-Sridhar PhD, RPh, MSc, BSc Phm, Assistant Professor, Departments of Medicine, Physiology and Pharmacology, University of Western Ontario; Assistant Professor, Department of Clinical Epidemiology and Biostatistics, McMaster University; Associate Director, Critical Care Research Network; Director of Health Informatics, Lawson Health Research Institute; CIHR New Investigator - Knowledge Translation, Ontario, Canada
Speakers: Elizabeth Manias RN, CertCritCare, MPharm, MNStud, PhD, FRCNA, MPS, Associate Head (Research), Equity and Staff Development Coordinator, Melbourne School of Health Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Carlton, Victoria, Australia; Maribel Salas, MD, DSc, MSc, Associate Medical Director, US Patient Safety, AstraZeneca, LP, Wilmington, DE, USA; Andrew Peterson  PhD, PharmD,  Interim Dean, Mayes College of Healthcare Business and Policy, University of the Sciences, Philadelphia, PA, USA

5:30PM-6:30PM ISPOR STUDENT FORUM: DEFINING YOUR CAREER PATH - FROM STRATEGIC JOB SEARCH SKILLS TO DECISION MAKING
A panel of experts will address how students should develop a strategy when searching for a job. What are the important issues a student should consider during a job search? How should curriculum vitae be modified to appeal to employers in various sectors? What are the pros and cons of jobs in industry versus academia versus consulting and what might help a graduate decide to take one position over another? Organized by the ISPOR Student Council

Moderators: ZZeba M. Khan RPh, PhD, Vice President, Pricing and Market Access, Celgene Corporation, New Jersey, USA, ISPOR Student Network Faculty Advisor; Milli Reddy BPharm, MS, Fulbright Scholar, Department of Pharmacy Administration, College of Pharmacy, The University of Texas at Austin, ISPOR Student Network Chair 2009-2010
Speakers:Michael Barry MD, PhD, FRCPI, 2009-2010 ISPOR President & Clinical Director, National Centre for Pharmacoeconomics, St. James’s Hospital and Senior Lecturer in Clinical Pharmacology, Trinity College Dublin, Dublin, Ireland; Bryan R. Luce, PhD, MBA, Senior Vice President, Science Policy, United BioSource Corporation, Bethesda, MD, USA; Scott D. Ramsey MD, PhD, 2009-2010 ISPOR President-Elect & Full Member and Professor, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA

5:30PM-6:30PM ISPOR Russia Chapter Forum
Reforms in drug supply in Russia: what's new?
The ISPOR Russia Regional Chapter has been involved in helping to bring forth reforms in the availability and access to prescription drugs for the Russian population.  This forum will focus on challenges and obstacles to equitable and effective drug supply system and the progress that has been made to improve the process. Presented by the ISPOR-Russia Regional Chapter

Moderator and Speaker: Pavel Vorobiev PhD, Professor, Moscow Medical Academy named after Sechenov, Head of the Research Department on Health Care Standardization Problems, President, ISPOR Russia Regional Chapter, Moscow, Russia
Speaker:  Oleg Borisenko MD, Executive Director, ISPOR Russia Regional Chapter Moscow, Russia

6:30PM-7:30PM
ISPOR FORUMS
6:30PM-7:30PM ISPOR Russia and Poland Regional Chapters Forum
How to provide patients proper access to innovative treatment : A perspective from Russia and Poland
The ISPOR Russia and ISPOR Poland Regional Chapters will discuss common issues facing their countries in gaining access for patients to the latest treatments.  Drug programs and their place in the health care system, access to the biological treatment in Poland, discussion on biologics in Russia and budget impact analysis as a tool for rational burden of drug budget exemplified by diabetes treatment for Polish patients will be presented.
Presented by the ISPOR Russia and ISPOR Poland Regional Chapters

Moderator and Speaker: Karina Jahnz-Rozyk PhD, Head of Department of Immunology and Allergology, Military Institute of Health Service, Warsaw, Poland
Speakers:  Pavel Vorobiev PhD, Professor, Moscow Medical Academy named after Sechenov, Head of the Research Department on Health Care Standardization Problems, President, ISPOR Russia Regional Chapter, Moscow, Russia, Oleg Borisenko MD, Executive Director, ISPOR Russia Regional Chapter, Moscow, Russia;Joanna Lis PhD, MBA, MSc, Manager of Health Economics Dept., Sanofi-Aventis, Warsaw, Poland

6:30PM-7:00PM
ISPOR ANNUAL BUSINESS MEETING
6:30PM-7:30PM
POSTER AUTHOR DISCUSSION HOUR – SESSION I
6:30PM-8:30PM
EXHIBITORS’ OPEN HOUSE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I
 



Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2010 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.
 
Website design by Eagle Systems USA, Inc.